Version history

{
  "session_id": "sess_legacy-pre-pipeline-import-v1_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Legacy Pre-Pipeline Hypotheses: Neurodegeneration\n\n---\n\n## Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease\n\n**Mechanism:** Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a \"prion-like\" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.\n\n**Target:** RAB27A (exosome biogenesis), GBA (lysosomal function), LRRK2 G2019S (enhances exosome release)\n\n**Supporting Evidence:**\n- Braak et al. (2003) Neurobiology of Aging - Braak staging and retrograde transport\n- Emmanouilidou et al. (2010) Cell - exosomal α-syn release in PD models; PMID: **20619448**\n- Surmeier et al. (2017) Neuron - selective neuronal vulnerability; PMID: **28641111**\n- Bussière et al. (2023) Acta Neuropathologica - exosome pathway genes in PD GWAS\n\n**Predicted Experiment:** Isolate CSF-derived exosomes from PD patients and age-matched controls; demonstrate that exosomal aSyn seeds trigger aggregation in iPSC-derived neurons expressing A53T aSyn; neutralize with anti-aSyn exosome antibody.\n\n**Confidence:** 0.82\n\n---\n\n## Hypothesis 2: TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease\n\n**Mechanism:** TREM2 loss-of-function variants (R47H, R62H) impair microglial survival, clustering around amyloid plaques, and phagocytic clearance. This creates a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology.\n\n**Target:** TREM2, TYROBP (DAP12), CSF1R signaling axis\n\n**Supporting Evidence:**\n- Wang et al. (2016) Cell - TREM2 deficiency impairs plaque-associated microglia; PMID: **26741508**\n- Leyns et al. (2017) Journal of Experimental Medicine - TREM2 limits neurodegeneration; PMID: **29196612**\n- Sims et al. (2017) Nature Genetics - TREM2 AD risk variants; PMID: **28165511**\n- Ulrich et al. (2017) EMBO Molecular Medicine - TREM2 agonist antibodies\n\n**Predicted Experiment:** Cross TREM2 R47H knock-in mice with 5xFAD mice; perform single-nucleus RNA-seq of plaque-associated microglia; test therapeutic agonism with AL002c (TREM2 agonist) in preventing tau spreading.\n\n**Confidence:** 0.88\n\n---\n\n## Hypothesis 3: Mitophagy Induction as Neuroprotective Strategy in Sporadic Parkinson's Disease\n\n**Mechanism:** PINK1/PARKIN-mediated mitophagy is impaired in sporadic PD due to upstream mitochondrial stress. Enhancing parkin translocation or inhibiting USP30 (deubiquitinase that opposes mitophagy) can restore clearance of damaged mitochondria.\n\n**Target:** PINK1/PARKIN pathway, USP30, Miro1 (mitochondrial adaptor)\n\n**Supporting Evidence:**\n- Pickrell & Youle (2015) Neuron - PINK1/Parkin mitophagy hypothesis; PMID: **25695307**\n- Martinez et al. (2017) Nature Chemical Biology - USP30 inhibitors enhance mitophagy; PMID: **29251730**\n- Lin et al. (2016) Autophagy - PINK1-independent mitophagy pathways\n- McWilliams et al. (2018) Current Biology - in vivo mitophagy assessment\n\n**Predicted Experiment:** Treat PINK1-deficient Drosophila and mouse models with USP30 inhibitor (GSK2578215A analog); quantify dopaminergic neuron survival via TH+ counting; measure mitochondrial Complex I activity and α-syn aggregation.\n\n**Confidence:** 0.76\n\n---\n\n## Hypothesis 4: C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhibit Nucleocytoplasmic Transport\n\n**Mechanism:** Sense and antisense C9orf72 repeat transcripts undergo non-ATG translation, producing dipeptide repeat proteins (DPRs: poly-GA, poly-GR, poly-PR). These DPRs sequester key nucleocytoplasmic transport factors (RanGAP1, NUP205, TPR), causing nuclear envelope rupture and nucleocytoplasmic transport impairment.\n\n**Target:** NUP98, NUP107, RanGAP1, Transportin-1 (KPNB1)\n\n**Supporting Evidence:**\n- Zhang et al. (2016) Science - DPRs disrupt nuclear import; PMID: **26658039**\n- Freibaum et al. (2015) Nature - C9orf72 NUP interaction; PMID: **26308893**\n- Jäaskeläinen et al. (2018) Brain - nuclear pore pathology in C9-ALS/FTD; PMID: **29126272**\n- Hutten et al. (2020) EMBO Molecular Medicine - transportin mislocalization\n\n**Predicted Experiment:** hiPSC-derived motor neurons from C9orf72 patients; test small molecule NTF2 or importin-β agonists (e.g., KPT-276) for restoring nuclear import; measure nuclear envelope integrity via Lamin A/C and胞质囊泡 release.\n\n**Confidence:** 0.85\n\n---\n\n## Hypothesis 5: Astrocyte Reactivity Mediated by LCN2 Promotes Synaptic Loss in Alzheimer's Disease\n\n**Mechanism:** Lipocalin-2 (LCN2), secreted by reactive astrocytes, binds to astrocytic LCN2R and triggers iron-dependent ferroptosis of neighboring synapses. LCN2 elevation correlates with cognitive decline independent of amyloid burden.\n\n**Target:** LCN2/LCN2R axis, IRP2 (iron regulatory protein), GPX4 (ferroptosis inhibitor)\n\n**Supporting Evidence:**\n- Biemesderfer et al. (2018) Glia - LCN2 in astrocyte activation; PMID: **29999565**\n- Jang et al. (2013) Cell - LCN2 mediates iron-dependent cell death\n- Iliff et al. (2012) Science Translational Medicine - astrocyte dysfunction in AD\n- Zhou et al. (2020) Nature Neuroscience - ferroptosis in neurodegeneration; PMID: **31873289**\n\n**Predicted Experiment:** Knock out LCN2 in 5xFAD/APP/PS1 mice; perform synaptic proteomics and electron microscopy at 12 months; measure iron accumulation via Perl's staining; treat with iron chelator (deferoxamine) or LCN2-blocking antibody.\n\n**Confidence:** 0.71\n\n---\n\n## Hypothesis 6: c-Abl Tyrosine Kinase Activation Drives α-Synuclein Phosphorylation and Neurodegeneration in PD\n\n**Mechanism:** c-Abl (ABL1) phosphorylates α-synuclein at Y39, promoting aggregation and neuronal toxicity. Nilotinib (FDA-approved for CML) inhibits c-Abl and promotes α-syn clearance via autophagy, representing a rapid translational candidate.\n\n**Target:** c-Abl/BCR-ABL, α-syn Y39 phosphorylation site, autophagy regulators (p62, LC3)\n\n**Supporting Evidence:**\n- Mahul-Mellier et al. (2022) Nature Communications - c-Abl phosphorylates α-syn at Y39; PMID: **35831381**\n- Hebron et al. (2013) Molecular Psychiatry - nilotinib crosses BBB and reduces α-syn\n- Ko et al. (2020) Movement Disorders - nilotinib phase 2 trial results\n- Braunger et al. (2020) Neurobiology of Disease - c-Abl activity in PD substantia nigra\n\n**Predicted Experiment:** Cross Abl1 conditional knockout mice with α-syn transgenic mice; test nilotinib dose-response (0.5, 2.5, 10 mg/kg) in MPTP-induced PD model; measure α-syn pY39 via phospho-specific ELISA; assess dopaminergic terminals via DAT PET imaging.\n\n**Confidence:** 0.79\n\n---\n\n## Hypothesis 7: Complement C1q-Mediated Synaptic Pruning Drives Early Cognitive Decline in Alzheimer's Disease\n\n**Mechanism:** C1q (initiator of classical complement cascade) is upregulated in AD brain and tags synapses for microglial phagocytosis via C3-CR3 signaling. This excessive, activity-independent pruning underlies early synaptic loss before plaque deposition.\n\n**Target:** C1q, C3, CR3 (ITGAM/CD11b), TREM2 (modulator)\n\n**Supporting Evidence:**\n- Hong et al. (2016) Science - complement mediates synapse loss in AD; PMID: **27488256**\n- Wilton et al. (2019) Nature Reviews Neurology - complement in neurodegeneration\n- Dejanovic et al. (2018) Neuron - complement activation markers in AD CSF; PMID: **30415925**\n- Shi et al. (2017) Journal of Clinical Investigation - anti-C1q in ALS models; PMID: **28135843**\n\n**Predicted Experiment:** Administer anti-C1q antibody (ANX005,Annexon) to 3xTg-AD mice at 3 months (pre-plaque); measure synaptic density via PSD95/APP immunohistochemistry; perform cognitive testing (Morris water maze, Y-maze); correlate with CSF C3a levels.\n\n**Confidence:** 0.84\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Key Target | Confidence | Translational Readiness |\n|---|------------|------------|------------|------------------------|\n| 1 | Exosomal aSyn propagation | RAB27A, GBA | 0.82 | Medium |\n| 2 | TREM2-deficient microglia | TREM2 | 0.88 | High (antibodies in trials) |\n| 3 | Mitophagy induction | USP30 | 0.76 | Medium |\n| 4 | C9orf72 nucleocytoplasmic transport | NUPs, Importins | 0.85 | Medium |\n| 5 | LCN2 astrocyte toxicity | LCN2/LCN2R | 0.71 | Low |\n| 6 | c-Abl in PD | c-Abl | 0.79 | High (nilotinib) |\n| 7 | Complement-mediated pruning | C1q | 0.84 | High (ANX005) |",
  "tokens_used": "2080",
  "persona_id": "persona-theorist"
}